Last reviewed · How we verify
NCT05174026
18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery
NA trial testing Fludeoxyglucose F-18 in Metastatic Malignant Neoplasm in 10 participants. Completed in 20 June 2024.
20 June 2024
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 10 |
| Start date | 30 November 2018 |
| Primary completion | 20 June 2024 |
| Estimated completion | 20 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fludeoxyglucose F-18 (FLUDEOXYGLUCOSE) — full drug profile →
- Magnetic Resonance Imaging
- Positron Emission Tomography
Conditions studied
- Metastatic Malignant Neoplasm — all drugs for Metastatic Malignant Neoplasm →
- Metastatic Malignant Neoplasm in the Bone — all drugs for Metastatic Malignant Neoplasm in the Bone →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Metastatic Malignant Neoplasm or Metastatic Malignant Neoplasm in the Bone. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well 18F-FDG PET-MRI works for treatment planning in patients with spine tumors. Diagnostic procedures, such as 18F-FDG PET-MRI may help radiation oncologists plan the best treatment for spine tumors, as well as help in follow-up after radiation therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current and Emerging Approaches for Spine Tumor Treatment.
Costăchescu B, Niculescu AG, Iliescu BF, Dabija MG, et al · · 2022 · cited 17× · PMID 36555324 · DOI 10.3390/ijms232415680
Verify or expand the search:
- PubMed search for NCT05174026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fludeoxyglucose F-18
Trials testing the same drug.
- NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
- NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
- NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
- NCT06502691 — [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Ca · Phase 1, PHASE2 · recruiting
- NCT07097363 — Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) · Phase 2 · recruiting
Other recruiting trials for Metastatic Malignant Neoplasm
Currently open trials in the same condition.
- NCT04150939 — Cryoablation for the Treatment of Metastatic Cancer · NA · active not recruiting
- NCT04068649 — Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer · Phase 2 · recruiting
- NCT03743649 — Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Under · Phase 2, PHASE3 · active not recruiting
- NCT04053517 — Financial Distress in Advanced Cancer Patients · active not recruiting
- NCT03671226 — Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their · NA · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05174026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 25 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05174026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing